In recent trading, shares of Gilead Sciences Inc (Symbol: GILD) have crossed above the average analyst 12-month target price of $111.77, changing hands for $112.26/share. When a stock reaches the ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gilead Sciences (GILD). Gilead ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline - - Interim Phase 1b proof-of-concept data, including initial efficacy ...